
Senti Biosciences Sets 1-for-33 Reverse Stock Split, Effective Nov. 18
Split-adjusted trading on Nasdaq is expected to begin Nov. 19 under the existing SNTI ticker, with a new CUSIP number.
Senti Biosciences Holdings, Inc. · Nasdaq · Biological Products, (No Diagnostic Substances)

Split-adjusted trading on Nasdaq is expected to begin Nov. 19 under the existing SNTI ticker, with a new CUSIP number.
No open-market insider buying or selling in the Form 4s filed since July 24, 2026.
Change in certifying accountant · Financial statements and exhibits
Amendments to articles or bylaws; fiscal year change · Financial statements and exhibits
AI summary, unreviewedSenti Biosciences (SNTI) effects 1-for-33 reverse stock split effective November 18, 2026, trading split-adjusted from November 19
Entry into a material definitive agreement · Unregistered sales of equity securities · Financial statements and exhibits
AI summary, unreviewedSenti Biosciences Holdings Signs Up to $4.55 Million Equity Commitment With Celadon-Affiliated Investor, Priced at Nasdaq Minimum Price
Departure/appointment of directors or officers · Other events
AI summary, unreviewedSenti Biosciences Announces Director Edward Mathers' Resignation and Sets October 30, 2026 Record Date for CVR Distribution